SOLIGENIX, INC.SNGXEarnings & Financial Report
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases, unmet medical needs in inflammatory disorders, and prophylactic vaccines for biodefense use cases. It operates primarily in the U.S. and global biotech markets, serving patient groups underserved by existing standard care options.
SNGX Q4 FY2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-3.7M
Net Profit
$-3.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.02
SOLIGENIX, INC. Q4 FY2024 Financial Summary
SOLIGENIX, INC. reported revenue of $0 for Q4 FY2024, with a net profit of $-3.0M (down 64.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-3.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
SOLIGENIX, INC. Annual Revenue by Year
SOLIGENIX, INC. annual revenue history includes year-by-year totals (for example, 2023 revenue was $839.4K).
SOLIGENIX, INC. Quarterly Revenue & Net Profit History
SOLIGENIX, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $0 | — | $-3.0M | N/A |
| Q3 FY2024 | $0 | — | $-1.7M | N/A |
| Q1 FY2024 | $117.0K | -54.5% | $-1.9M | -1636.6% |
| Q4 FY2023 | $244.8K | -33.1% | $-1.8M | -743.4% |
| Q3 FY2023 | $130.4K | -21.5% | $-1.7M | -1274.7% |
| Q2 FY2023 | $206.9K | -9.5% | $-1.6M | -779.0% |
| Q1 FY2023 | $257.2K | +36.8% | $-1.0M | -406.8% |
| Q4 FY2022 | $366.1K | +32.8% | $-3.8M | -1025.4% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $366068 | $257178 | $206929 | $130440 | $244812 | $117029 | $0 | $0 |
| YoY Growth | 32.8% | 36.8% | -9.5% | -21.5% | -33.1% | -54.5% | N/A | N/A |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.3M | $11.1M | $13.8M | $11.3M | $9.8M | $8.1M | $10.5M | $9.0M |
| Liabilities | $16.8M | $14.5M | $8.0M | $7.1M | $7.3M | $7.3M | $4.5M | $4.8M |
| Equity | $-2.5M | $-3.4M | $5.8M | $4.2M | $2.5M | $768372 | $5.9M | $4.1M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.6M | $-2.2M | $-1.9M | $-2.7M | $-1.8M | $-1.3M | $-2.9M | $-2.2M |